(19)
(11) EP 3 280 432 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.04.2021 Bulletin 2021/15

(45) Mention of the grant of the patent:
10.03.2021 Bulletin 2021/10

(21) Application number: 16777107.0

(22) Date of filing: 04.04.2016
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07K 14/00(2006.01)
C07K 16/10(2006.01)
C07K 14/435(2006.01)
A61K 38/17(2006.01)
 A61K 38/00(2006.01)
C07K 14/705(2006.01)
C07K 16/28(2006.01)
G01N 33/574(2006.01)
(86) International application number:
PCT/US2016/025868
(87) International publication number:
WO 2016/164305 (13.10.2016 Gazette 2016/41)

(54)

DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF

DE-NOVO-BINDUNGSDOMÄNE MIT POLYPEPTIDEN UND VERWENDUNGEN DAVON

POLYPEPTIDES CONTENANT UN DOMAINE DE LIAISON DE NOVO ET LEURS UTILISATIONS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.04.2015 US 201562143772 P

(43) Date of publication of application:
14.02.2018 Bulletin 2018/07

(60) Divisional application:
21155053.8

(73) Proprietors:
  • Subdomain, LLC
    Washington, DC 20015 (US)
  • Arcellx, Inc.
    Gaithersburg, MD 20878 (US)

(72) Inventors:
  • LAFLEUR, David, William
    Washington, DC 20015 (US)
  • HILBERT, David, M.
    Gaithersburg, MD 20878 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
WO-A1-2010/124829
US-A1- 2014 271 582
 WO-A1-2014/138805
   
  • PER-ÅKE NYGREN: "Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold : Affibody binding proteins", FEBS JOURNAL, vol. 275, no. 11, 24 April 2008 (2008-04-24), pages 2668-2676, XP055504842, GB ISSN: 1742-464X, DOI: 10.1111/j.1742-4658.2008.06438.x
  • NOAD R ET AL: "Virus-like particles as immunogens", TRENDS IN MICROBIOLOGY, ELSEVIER SCIENCE LTD., KIDLINGTON, GB, vol. 11, no. 9, 1 September 2003 (2003-09-01), pages 438-444, XP003004438, ISSN: 0966-842X, DOI: 10.1016/S0966-842X(03)00208-7
  • ANDREAS PL?CKTHUN: "Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 55, no. 1, 6 January 2015 (2015-01-06), pages 489-511, XP055217451, ISSN: 0362-1642, DOI: 10.1146/annurev-pharmtox-010611-134654
  • DAVID LAFLEUR ET AL: "Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides", MABS, vol. 5, no. 2, 1 March 2013 (2013-03-01), pages 208-218, XP055196030, ISSN: 1942-0862, DOI: 10.4161/mabs.23043
  • PLUCKTHUN.: 'Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy.' ANNU REV PHARMACOL TOXICOL. vol. 55, January 2015, pages 489 - 511, XP055217451
  • WALKER ET AL.: 'Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD 246).' J IMMUNOTHER CANCER vol. 2, no. SUPPL, 2014, page P40, XP021202601
  • MARDIROS ET AL.: 'T cells expressing CD 123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.' BLOOD vol. 122, no. 18, 2013, pages 3138 - 3148, XP002727946
  • DATABASE UNIPROT [Online] 07 January 2015 'Cytoplasmic dynein 2 heavy chain 1.', XP055488729 Retrieved from UNIPROTKB Database accession no. 9ZSS7
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).